OncoMatch/Clinical Trials/NCT06155383
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Is NCT06155383 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Capecitabine and oxaliplatin for gastric cancer.
Treatment: Capecitabine · oxaliplatin · Disitamab Vedotin · Toripalimab — The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) expression: IHC 1+, 2+, 3+ (IHC 1+, 2+, or 3+)
HER2- expression: IHC 1+, 2+, 3+
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any anti-tumor therapy
had not previously received any antitumor therapy for gastric or gastroesophageal junction adenocarcinoma
Lab requirements
Blood counts
ANC ≥1.5×10^9/L (no G-CSF within 1 week); Platelets ≥100×10^9/L (no transfusion within 1 week, no rhTPO within 2 weeks); Hemoglobin ≥9g/dL (no transfusion or erythropoietin within 2 weeks)
Kidney function
Blood creatinine ≤1.5x ULN or creatinine clearance (CrCl) ≥50 mL/min
Liver function
Serum total bilirubin ≤1.5x ULN; ALT and AST ≤2.5x ULN
Cardiac function
left ventricular ejection fraction ≥50%
Bone marrow function: ANC ≥1.5×10^9/L... Hemoglobin ≥9g/dL... Liver function: Serum total bilirubin ≤1.5x ULN; ALT and AST ≤2.5x ULN... Kidney function: Blood creatinine ≤1.5x ULN or CrCl ≥50 mL/min... Cardiac function: left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06155383 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 expression: IHC 1+, 2+, 3+ is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify